OneTest is a cutting edge blood test that can help detect many common cancers at early, more treatable stages. Many of the cancers OneTest can help detect are the same aggressive cancers that firefighters are at higher risk for.
What is the critical gap in cancer treatment that you are addressing?
Every day of the year, firefighters put their lives on the line protecting our homes and communities from the ravages of fires and natural disasters, despite taking known risks to their own safety and well-being. The constant, daily exposure to environmental hazards and cancer-causing toxins such resulting from burning homes and cars, is leading to higher incidences of cancer among younger firefighters. In addition to the more common cancers of the lung, colon, and prostate, other rare tumors such as the esophagus, intestine, rectum, and bladder are being detected in firefighters at an earlier and sometimes more aggressive stage. The detection of these rare malignancies is hardly mentioned by the U.S. Preventative Task Force, American Cancer Society, and other leading cancer groups, however, this is proven in a study from the National Institute for Occupational Safety and Health.
20/20 Gene Systems has developed the OneTest – a unique, six “biomarker” screening test to help indicate the presence of certain common cancers. We are working with the Fire Fighters Cancer Foundation to make this test available to active and retired firefighters nationwide. OneTest will help detect cancer early for firefighters, enabling them to get treated while their cancers are at earlier stages. We believe the OneTest can dramatically improve the survival outcomes for firefighters who have been diagnosed with cancer.
What is the key product development milestone you seek to fund?
OneTest is a simple blood test that assists in the earlier detection of multiple cancers including but not limited to lung, liver, esophagus, pancreas, stomach, prostate, testicular, cervical, ovarian, breast, and mesothelioma. The foundation of OneTest is the measurement of a panel of protein biomarkers found in the blood.
The underlying biomarkers used in OneTest are well known but limited as they are traditionally used in isolation to determine the potential presence of a tumor. OneTest deploys powerful “artificial intelligence” technology that can examine an individual’s biomarker levels and other characteristics such as age, gender and instantly compare it against a database of nearly 100,000 individuals tested over the past 12 years for these biomarkers with known cancer outcomes. Additionally, with every exposure to new patients data, OneTest uses “machine learning” to improve its accuracy even further over time.
The OneTest tumor marker panel includes the following six biomarkers: CEA, CA-125, AFP, CA-19-9, PSA, and Cyfra 21-1. In men, CA125 is substituted for PSA. OneTest is not FDA approved; however, each individual marker carries with it FDA approval granted to the kit manufacturer for serial monitoring.
The intended use of funding will be the continued enhancement and validation of our machine learning algorithms, specifically designed to improve early detection among firefighters. This project will serve as a “fast track” mechanism for improving future assessment models. By continuing to build this database with OneTest results from firefighters, it will ultimately serve as a huge benefit for the general population.
How will funds be used?
Funds raised from this campaign will be used for the following:
What key resources have/will you acquire to facilitate the accomplishment of the above R&D milestone?
20/20 Gene Systems is strategically partnered with Fire Fighter Cancer Foundation to help reach local and remote fire departments – bringing OneTest capabilities and support to these communities.
In addition 20/20 Gene Systems will be forming strategic partnerships with wellness centers and mobile phlebotomy (blood drawing) stations and units in key areas to enable firefighters to gain easier access to this part of the service which is essential. We are also forming key relationships with insurance providers to place OneTest under their cancer screening and prevention programs.
Under Mr. Cohen’s leadership, 20/20 GeneSystems has brought in approximately $7.5 million in grant funding and launched two successful products, a kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for the early detection of lung cancer. He is the co-inventor of an AI approach for improving tumor biomarker accuracy. Mr. Cohen forged strategic alliances with Fortune 500 companies such as Johnson & Johnson, Eastman Kodak, Abbott Diagnostics, Smiths Detection, and Ping An Ventures, the investment arm of the largest insurance company in China. Mr. Cohen is a registered patent attorney with more than 18 years of experience in biotechnology patents and licensing matters. He has a Master of Science in Biotechnology from Johns Hopkins University and a law degree from the American University.
Ron has been involved in the healthcare sector for his entire career, primarily focusing on providing innovative oncology products and services to hospitals, physicians, pharmaceutical and biotech companies in the US, Europe and Asia. His areas of responsibility include Sales, Marketing, Customer Services, Management and Operations. He holds a B.S. in Biology and MBA in Management.
David is the sales manager 20/20 Genesystems Inc. David has held this position for 2 years and has strong relationships with firefighter associations across the nation. David earned a B.S. in Biochemistry from Christopher Newport University in VA.